Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retinoic acid tablets plus decitabine versus decitabine alone for untreated MDS with excess blasts
ChiCTR1800018307Phase 4Completed
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in myelodysplastic syndrome with excess blasts (MDS-EB) comparing Retinoic acid tablets combined with decitabine with Decitabine (2 arms). Primary endpoint: Overall response rate by independent review committee. Started Aug 2018; status: completed.
02
Drugs
tretinoindecitabine
03
Conditions
myelodysplastic syndrome with excess blasts (MDS-EB)
Beyond the preview
Go deeper on ChiCTR1800018307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018307.